SG Americas Securities LLC Cuts Stock Position in Immunocore Holdings plc (NASDAQ:IMCR)

SG Americas Securities LLC trimmed its holdings in Immunocore Holdings plc (NASDAQ:IMCR) by 94.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,800 shares of the company’s stock after selling 151,558 shares during the period. SG Americas Securities LLC’s holdings in Immunocore were worth $274,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in IMCR. Candriam S.C.A. raised its position in shares of Immunocore by 65.8% during the second quarter. Candriam S.C.A. now owns 313,423 shares of the company’s stock valued at $10,621,000 after buying an additional 124,417 shares during the last quarter. Frazier Life Sciences Management L.P. bought a new stake in Immunocore in the 2nd quarter valued at $3,686,000. Janus Henderson Group PLC increased its holdings in Immunocore by 45.8% in the 1st quarter. Janus Henderson Group PLC now owns 257,080 shares of the company’s stock valued at $16,711,000 after acquiring an additional 80,748 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in Immunocore by 16.2% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 397,463 shares of the company’s stock valued at $13,470,000 after acquiring an additional 55,463 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Immunocore by 14.5% in the 2nd quarter. Renaissance Technologies LLC now owns 646,920 shares of the company’s stock valued at $21,924,000 after acquiring an additional 82,120 shares during the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Immunocore Price Performance

IMCR stock opened at $34.38 on Monday. Immunocore Holdings plc has a 12 month low of $29.72 and a 12 month high of $76.98. The company has a current ratio of 5.17, a quick ratio of 5.15 and a debt-to-equity ratio of 1.31. The company has a 50-day moving average price of $33.75 and a 200 day moving average price of $41.89. The stock has a market cap of $1.72 billion, a PE ratio of -28.18 and a beta of 0.72.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.25. Immunocore had a negative net margin of 19.16% and a negative return on equity of 14.68%. The firm had revenue of $75.40 million during the quarter, compared to analysts’ expectations of $74.58 million. During the same period in the previous year, the company earned ($0.37) EPS. The firm’s revenue for the quarter was up 26.2% compared to the same quarter last year. Equities research analysts anticipate that Immunocore Holdings plc will post -1.67 earnings per share for the current year.

Wall Street Analyst Weigh In

IMCR has been the topic of a number of research reports. Barclays reduced their price target on shares of Immunocore from $92.00 to $66.00 and set an “overweight” rating on the stock in a report on Friday, August 9th. Needham & Company LLC reduced their price target on shares of Immunocore from $81.00 to $78.00 and set a “buy” rating on the stock in a report on Tuesday, September 17th. Oppenheimer reiterated an “outperform” rating and issued a $89.00 price target (up from $87.00) on shares of Immunocore in a report on Friday, August 9th. Morgan Stanley reduced their price target on shares of Immunocore from $80.00 to $74.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research note on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Immunocore presently has an average rating of “Moderate Buy” and an average price target of $79.82.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.